Dose and Administration: 500 mg 4 times daily during menstruation
Indications: indicated in patients with hemophilia for short-term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy.
Contraindications: In patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as a measure of toxicity. In patients with subarachnoid hemorrhage. In patients with active intravascular clotting.
Dose and Administration: By mouth, local fibrinolysis, 15–25 mg/kg 2–3 times daily. Menorrhagia (initiated when menstruation has started), 1 g 3 times daily for up to 4 days; max. 4 g daily. Hereditary angioedema, 1–1.5 g 2–3 times daily Epistaxis, 1 g 3 times daily for 7 days.By slow intravenous injection, local fibrinolysis, 0.5–1 g 3 times daily.